Prosecution Insights
Last updated: October 02, 2026

Examiner: WERTZ, ASHLEE ELIZABETH

Tech Center 1600 • Art Units: 1600 1612 1626

This examiner grants 53% of resolved cases

Analysis

Ashlee Elizabeth Wertz has resolved 49 cases in Art Unit 1600, with an allowance rate of 51.0 percent. The median days to allowance is 1229, reflecting the typical challenges of Tech Center 1600. This rate suggests a moderate level of difficulty for applicants, with about half of the resolved cases resulting in a grant. Practitioners should be prepared for a prosecution cycle that lasts 1229 days.

The interview lift of 39.7 percent is a strong indicator of the examiner's receptivity to verbal discussion. This lift significantly boosts the 51.0 percent baseline, making interviews a highly effective tactic for overcoming rejections. Practitioners should use interviews to clarify technical points and move toward an allowance more efficiently. The 39.7 percent lift is a key metric, suggesting that many issues can be resolved through direct dialogue that might otherwise lead to further rejections. Given the 1229-day median pendency, an interview could also help to expedite the process. The data from 49 cases shows that while the examiner is thorough, they are also very open to the collaborative interview process, which can provide a major boost to the chances of success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

52.9%
Allow Rate
-7.1% vs TC avg
107
Total Applications
+42.1%
Interview Lift
1237
Avg Prosecution Days
Based on 51 resolved cases, 2023–2026

Rejection Statute Breakdown

0.5%
§101 Eligibility
6.7%
§102 Novelty
48.4%
§103 Obviousness
15.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18062575 HEMOSTATIC MATERIAL COMPOSITION Non-Final OA FUJIFILM CORPORATION
18291707 PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS Final Rejection ModernaTX, Inc.
17915587 Aqueous Formulations of Dicamba Non-Final OA BASF CORPORATION
18255490 FUNGICIDAL COMPOSITIONS Non-Final OA SYNGENTA CROP PROTECTION AG
17988191 METHODS, COMPOSITIONS AND APPARATUS FOR COATING BONE MATERIAL Non-Final OA Warsaw Orthopedic, Inc.
18748644 CELLULOSIC FIBER BLENDS FOR DISINFECTING WIPES WITH IMPROVED TEAR STRENGTH Final Rejection ECOLAB USA INC.
18114937 Oral Care Compositions Final Rejection Kenvue Brands LLC
18114950 Oral Care Compositions Final Rejection Kenvue Brands LLC
18255660 SOLID COMPOSITION COMPRISING A COMBINATION OF PARTICULAR ANIONIC SURFACTANTS AND AT LEAST ONE CATIONIC POLYSACCHARIDE Final Rejection L'OREAL
17956991 COMPOSITIONS AND METHODS FOR STYLING HAIR Final Rejection L'OREAL
17852729 COMPOSITIONS AND METHODS FOR STYLING HAIR Final Rejection L'Oreal
18761018 ISOMER-SPECIFIC NEUROPROTECTIVE EFFECT OF NATURAL RESERVATROL Non-Final OA University of South Carolina
18691616 COSMETIC COMPOSITION Final Rejection SHISEIDO COMPANY, LTD.
17790010 Personal Care Compositions Final Rejection Colgate-Palmolive Company
18791989 INSECT REPELLENT POLYETHYLENE TEREPHTHALATE FIBERS Non-Final OA The Government of the United States of America, as represented by the Secretary of the Navy
17996391 SELF-TANNING COMPOSITIONS CONTAINING AN ALKYL SULFONATE AND METHODS THEREOF Non-Final OA Kao Corporation
17998050 CO-GROUND ACTIVE(S) COMPRISING PRODUCT COMPRISING SURFACE-REACTED CALCIUM CARBONATE Final Rejection Omya International AG
18005404 COOLING SENSATION COMPOSITIONS Non-Final OA GIVAUDAN SA
18567872 HEXAGONAL BORON NITRIDE POWDER AND METHOD FOR PRODUCING SAME, AND COSMETICS AND METHOD FOR MANUFACTURING SAME Non-Final OA Denka Company Limited
18267619 FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES Final Rejection FMC CORPORATION
18084539 COMPOSITIONS CONTAINING ORGANIC ACIDS AND THEIR ESTERS TO PREVENT MOLD CONTAMINATION IN ANIMAL FEED Non-Final OA KEMIN INDUSTRIES, INC.
18571558 SUSPENDING POLYMER COMPOSITION AND METHOD OF USE THEREOF Final Rejection ISP Investments LLC
18019786 Method for Producing Microcapsules Final Rejection Symrise AG
18291808 LIPID NANOPARTICLE FORMULATIONS Non-Final OA Monash University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month